NO143381B - Analogifremgangsmaate ved fremstilling av farmakologisk aktive guanidin- og isotioureaderivater - Google Patents
Analogifremgangsmaate ved fremstilling av farmakologisk aktive guanidin- og isotioureaderivater Download PDFInfo
- Publication number
- NO143381B NO143381B NO750809A NO750809A NO143381B NO 143381 B NO143381 B NO 143381B NO 750809 A NO750809 A NO 750809A NO 750809 A NO750809 A NO 750809A NO 143381 B NO143381 B NO 143381B
- Authority
- NO
- Norway
- Prior art keywords
- formula
- histamine
- methyl
- group
- preparation
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 5
- 238000002360 preparation method Methods 0.000 title claims description 3
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 title 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 title 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 26
- 150000003839 salts Chemical class 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 4
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 40
- 229960001340 histamine Drugs 0.000 description 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 239000000739 antihistaminic agent Substances 0.000 description 4
- 229940125715 antihistaminic agent Drugs 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- RIMGDBZXWSGBQN-UHFFFAOYSA-N burimamide Chemical compound CNC(=S)NCCCCC1=CN=C[N]1 RIMGDBZXWSGBQN-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- BXXGTPDBOUVLLF-UHFFFAOYSA-N methyl n,n'-bis[2-[(5-methyl-1h-imidazol-4-yl)methylsulfanyl]ethyl]carbamimidothioate;trihydrochloride Chemical compound Cl.Cl.Cl.N1=CNC(C)=C1CSCCN=C(SC)NCCSCC=1N=CNC=1C BXXGTPDBOUVLLF-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 3
- -1 2-((5-methyl-4-imidazolyl)methylthio)ethyl Chemical group 0.000 description 2
- ZFIVZTUNAWCKQB-UHFFFAOYSA-N 2-(1,3-thiazol-2-ylmethylsulfanyl)ethylthiourea Chemical compound NC(=S)NCCSCC1=NC=CS1 ZFIVZTUNAWCKQB-UHFFFAOYSA-N 0.000 description 2
- CIGPGCNMPFKLRK-UHFFFAOYSA-N 2-methyl-1,3-bis[2-[(5-methyl-1h-imidazol-4-yl)methylsulfanyl]ethyl]guanidine Chemical compound N1=CNC(C)=C1CSCCNC(=NC)NCCSCC=1N=CNC=1C CIGPGCNMPFKLRK-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- MDKCFLQDBWCQCV-UHFFFAOYSA-N benzyl isothiocyanate Chemical compound S=C=NCC1=CC=CC=C1 MDKCFLQDBWCQCV-UHFFFAOYSA-N 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 230000027119 gastric acid secretion Effects 0.000 description 2
- 229940071870 hydroiodic acid Drugs 0.000 description 2
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- URZFVRZJQHCTGN-UHFFFAOYSA-N 1,3-bis[2-[(5-methyl-1h-imidazol-4-yl)methylsulfanyl]ethyl]thiourea Chemical compound N1=CNC(CSCCNC(=S)NCCSCC2=C(N=CN2)C)=C1C URZFVRZJQHCTGN-UHFFFAOYSA-N 0.000 description 1
- WAIHMWWSWLOHNH-UHFFFAOYSA-N 2-(1,3-thiazol-2-ylmethylsulfanyl)ethanamine Chemical compound NCCSCC1=NC=CS1 WAIHMWWSWLOHNH-UHFFFAOYSA-N 0.000 description 1
- JEOZNMMOIBLWLV-UHFFFAOYSA-N 2-[(5-methyl-1h-imidazol-4-yl)methylsulfanyl]ethanamine Chemical compound CC=1N=CNC=1CSCCN JEOZNMMOIBLWLV-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000000543 Histamine Receptors Human genes 0.000 description 1
- 108010002059 Histamine Receptors Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- QAADZYUXQLUXFX-UHFFFAOYSA-N N-phenylmethylthioformamide Natural products S=CNCC1=CC=CC=C1 QAADZYUXQLUXFX-UHFFFAOYSA-N 0.000 description 1
- 108010079943 Pentagastrin Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000005242 cardiac chamber Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N ethyl acetate Substances CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
- 229960000582 mepyramine Drugs 0.000 description 1
- HNYUEMFTHSYPCW-UHFFFAOYSA-N n-[2-(1,3-thiazol-2-ylmethylsulfanyl)ethylcarbamothioyl]benzamide Chemical compound C=1C=CC=CC=1C(=O)NC(=S)NCCSCC1=NC=CS1 HNYUEMFTHSYPCW-UHFFFAOYSA-N 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- ANRIQLNBZQLTFV-DZUOILHNSA-N pentagastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1[C]2C=CC=CC2=NC=1)NC(=O)CCNC(=O)OC(C)(C)C)CCSC)C(N)=O)C1=CC=CC=C1 ANRIQLNBZQLTFV-DZUOILHNSA-N 0.000 description 1
- 229960000444 pentagastrin Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003585 thioureas Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/26—Radicals substituted by sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
Foreliggende oppfinnelse vedrører en analogifremgangsmåte
ved fremstilling av farmakologisk aktive forbindelser med formelen (I)
og salter derav,
hvori R-^ er en gruppe med formel (II) :
hvori Het er en imidazolyl eller tiazolylgruppe, hvilke grupper eventuelt er substituert med en C-^^-alkylgruppe, R2 er hydrogen, en C^^-alkylgruppe eller en gruppe med formel
(II), X er 5 eller NH, men ikke NH når R er hydrogen, og
er C1_4~alkyl.
Forbindelsene fremstilt ifølge oppfinnelsen kan forekomme i form av syreaddisjonssalter, men for enkelhets skyld vil det gjennom beskrivelsen bli referert til parentalforbindelsen.
Mange fysiologisk aktive stoffer får fremkalt sine biologiske virkninger ved vekselvirkning med bestemte steder, som er kjent som receptorer. Histamin er et slikt stoff og har et antall av biologiske virkninger. De av histamins biologiske virkninger, som inhiberes av medikamenter, som vanligvis blir kalt "antihistaminer", på hvilke mepytamin er et typisk eksempel, formidles ved mellomkomst av histamin H-^-receptorer (Ash and Schild, Brit.J.Pharmac.Chemother, 27, 427, (1966)). Andre av histamins biologiske virkninger inhiberes imidlertid ikke av "antihistaminer", og virkningen av denne type, som inhiberes ved hjelp av en forbindelse beskrevet av Black et al. (Nature, 236, 385 (1972)) og omtalt som burimamid, formidles ved mellomkomst av receptorer, som av Black et al, er definert som histamin I^-receptorer. Histamin I^-receptorer kan således defineres som de histamin-receptorer, som ike blokkeres av mepyramin, men som blokkeres av burimamid. Forbindelser som blokkerer histamin H9-receptorer, omtales som histamin H0-antagonister.
Blokkering av histamin I^-receptorer er nyttig til inhibering
av de av histamins biologiske virkninger, som ikke inhiberes av "antihistaminer". Histamin H2-antagonister er derfor anvendelige, f.eks. som inhibitorer av mavesyresekresjon, som antiinflamma-toriske midler og som midler som innvirker på det kardiovasku-lære system. Ved behandling av visse tilstander, f.eks. beten-nelse, er en kombinasjon av histamin H-^- og I^-antagonister nyttig.
Det vil forståes at den i formel I viste oppbygning kun er en av flere mulige, og at andre tautomere former også faller inn under den foreliggende oppfinnelse.1
Forbindelsene av formelen I fremstilles ifølge oppfinnelsen ved at en forbindelse med formelen (III): R-.NHC'^^5^ (III)
-NHR2
alkyleres med et alkyleringsmiddel som tilfører C1_4-gruppen R^, og hvoretter når en forbindelse med formel (I) er ønsket hvori X er NH, omsette det erholdte produkt med et amin med formelen (IV):
R3NH9 (IV)
hvori R3 har den i forbindelse med formel (I) angitte betydning, hvoretter en forbindelse med formel (I) om ønskes omdannes til et salt.
Tioureaene av formelen III kan fremstilles ved fremgangsmåter, som er beskrevet og bl.a. påberopt i britisk patentskrift nr. 1.330.169 og tysk offenliggjøringsskrift nr. 2.433.625.
Forbindelsene med formelen I blokkerer histamin I^-receptorer,
dvs. at de inhiberer de av histamins biologiske virkninger som ikke inhiberes av "antihistaminer", slik som mepyrarnin, men inhiberes av burimamid. F.eks. har forbindelsene fremstilt ifølge oppfinnelsen vist seg å inhibere histaminstimulert sekresjon av mavesyre fra lumenperfuserte maver fra rotter, som er bedøvet med uretan, i doser på 0,5 - 256 mikromol pr. kg. intravenøst. Denne prosedyre er omtalt i det ovenfor nevnte skrift av Ash og Schild. Virkningen av disse forbindelser som histamin f^-antagonister fremgår også av forbindelsenes evne til å inhibere andre virk-ninger av histamin, som ifølge ovenfor ne^vnte skrift av Ash og Schild, ikke formidles av histamin H-^-receptorer. F.eks. inhiberer de virkningene av histamin på det isolerte hjerteforkam-
mer fra marsvin og på isolert rotteuturus.
Forbindelsene fremstilt ifølge oppfinnelsen inhiberer den grunnleggende sekresjon av mavesyre og også den sekresjon som stimuleres av pentagastrin eller av fode.
Ytterligere har forbindelsene fremstilt ifolge oppfinnelsen anti-inflammatorisk virkning ved konvensjonelle forsok, slik som rotte-poteodemforsok, hvor odemet fremkalles ved hjelp av et irritasjonsmiddel og rottepotevolumet forminskes ved hjelp av subkutant injeksjon av doser av en forbindelse av formel I.
Ved et konvensjonelt forsok, slik som måling av blodtrykk hos
en bedovet katt, kan virkningen av forbindelsene fremstilt ifolge oppfinnelsen for inhibering av den vasodilatoriske virkning av histamin også demonstreres. Virkningsgraden for forbindelsene frémstilt ifolge oppfinnelsen illustreres av den effektive dosis, som fremkaller 5o% inhibering av mavesyresekresjon hos den bedovede rotte, og den dose, som fremkaller 5o% inhibering av histamin-indusert tachycardi i det isolerte hjerteforkammer fra marsvin.
For terapeutisk anvendelse vil de farmakologisk aktive forbindelser fremstilt ifolge oppfinnelsen normalt bli administrert som et farmsoytisk preparat omfattende som den vesentlige aktive bestanddel eller som en vesentlig aktiv bestanddel minst én slik, forbindelse i basisk form eller i form av et syreaddisjonssalt med en farmsoytisk akseptabel syre og i fobindelse med en farma-søytisk bærer derfor. Slike addisjonssalter innbefatter salter med saltsyre, hydrogenbcomidsyre, hydrogenjodidsyre, svovelsyre og maleinsyre og kan hensiktsmessig dannes ut fra de tilsvarende baser av formelen I ved hjelp av standardprosedyrer, f.eks.
ved behandling av basen med en syre i en lavere alkanol, eller under anvendelse av ionebytterharpikser for dannelse av det onskede salt, enten direkte ut fra basen eller ut fra et fra basen forskjellig addisjonssalt.
Oppfinnelsen illustreres i de etterfølgende eksempler, hvor alle temperaturer er «anført i °C.
EKSEMPEL 1
S-metyl-N-/2-((5-metyl-4-imidazolyl)metyltio)etyl/isotioureahydrojodid.
En blanding av N-/2-((5-metyl-4-imidazolyl)metyltio)etyl/tiourea (2.29 g) og metyljodid (1,56 g) i aceton (45 ml) inneholdende metanol (5 ml) ble henstilt i 18 timer ved romtemperatur. Konsentrering etterfulgt av rekrystallisering fra isopropylalkohol-petroleumseter (kokepunkt 6o/8o°C) resulterte i den i overskriften nevnte forbindelse (2,3 g) med smp. 128-131°C.
(Funnet: C 28,8, H 4, 5, N 14,8, S 17,5, I 33,<8,><C>9H16<N>4<S>2 innebærer: C 29,o, H 4,6, N 15,1, S 17,2, I 34,1%).
EKSEMPEL 2
N,S-dimetyl-N'~/ 2-((5-metyl-4-imidazolyl)metyltio)etyl7-isotio-ureadihydrojodid.
N-metyl-N'-/ 2-((5-metyl-4-imidazolyl)metyltio)etyl7tiourea
(lo,o g) ble opplost i metanol (4oo ml), og det ble tilsatt 55% vandig hydrogenjodidsyre (12,2 ml) etterfulgt av metyljodid (5,3 ml). Opplosningen ble oppvarmet under tilbakekjoling i 4 timer og konsentrert. Den tilbakeblivende rest ble oppløst i metanol (loo ml) og det ble tilsatt eter for oppnåelse av det i overskriften anførte produkt i form av dihydrojodidet
(5,48 g) med smp. 185-186°C (fra isopropylalkohol).
(Funnet: C 23,4, H, 3,9, I 49,6, S 12,6, CloH18N4S2.2HI innebærer: C 23,4, H 3,9, N lo,9, I 49,4, S 12,5%).
EKSEMPEL 3
S-metyl-N,N' -bis-[2- ( (5-metyl-4-imidazolyl)metyltio) etyl] - isotioureatrihydroklorid.
(1) En oppløsning av 4-metyl-5- ( (2-a'minoetyl) tiometyl) imidazol
(34,0 g) og karbondisulfid (7,6 .g) i etanol (250 ml) ble oppvarmet under tilbakekjøling i 6 timer. Konsentrering etterfulgt av kromatografisk rensing av produktet på en silikagelsøyle med
eluering ved hjelp av isopropylalkohol-etylacetat etterfulgt av isopropylalkohol-etanol resulterte i N,N<1->bis-[2-((5-mety1-4-imidazolyl)metyltio)etyl]tiourea (10 g) med smp. 133-135°C.
(Funnet: C 47,0, H 6,1, N 22,<0,><C>15<H>24N6<S>3
innebærer C 46,8, H 6,3, N^21,9%).
(2) Tørt hydrogenklorid ble ført inn i en oppløsning av N,N'-bis-[2-((5-metyl-4-imidazolyl)metyltio)etyl]tiourea (7,7 g) i metanol ved 80°C i 5 timer. Konsentrering og gjeninndampning med isopropylalkohol resulterte i S-metyl-N,N'-bis-[2-((5-metyl-4-imidazolyl)metyltio)etyl]isotioureatrihydroklorid (9,0 g) med smp. 212-215°C (isopropylalkohol).
Funnet: C 37,6, H 5,7, N 16,3, S 18,6, Cl 20,5, cx6H2<6N6S3>' 3HC1
innebærer C 37,8, H 5,8, N 16,5, S 18,9, Cl 20,9%).
EKSEMPEL 4
N,N'-bis-[2-((5-metyl-4-imidazolyl)metyltio)etyl]-N"-metyl-guanidin.
En oppløsning av N,N '-bis-[2- ( (5-metyl-4-imidazolyl)metyltio) - etyl]-S-metylisotioureatrihydroklorid (2,0 g) i 33 % etanolisk metylamin (60 ml) ble oppvarmet under tilbakekjøling i 3 timer. Blandingen ble gjort basisk med natriummetoksyd, filtrert og filtratet ble konsentrert under redusert trykk. Behandlingen av resten med etanolisk pikrinsyre resulterte i N,N'-bis-[2-((5-metyl-4-imidazolyl)metyltio)etyl]-N"-metylguanidintripi-krat (2,8 g) med smeltepunkt 169-170°C.
(Funnet: C 38,o, H 3,4, N 2o,7, S 6,o, C,CH^ N S„,
lo 2 1 12.
3C6H3N307
innebærer: C 38,2, H 3,4, N 21,o, S 6,o%).
Behandlingen av tripikratet med saltsyre og fjerning av pikrin-syren ved ekstraksjon med toluen resulterte i trihydrokloridet.
EKSEMPEL 5
S-metyl-N-2-(2-tiazolylmetyltio)etyl isotioureahydrojodid
a) En blanding av 2-(2-tiazolylmetyltio)etylamin (fra 30 g av dihydrobromidet), benzyl isotiocyanat (14,0 g) og diklormetan
(100 ml) ble kokt under tilbakeløp i 2 h og avkjølt. Det hvite faststoff som utkrystallisertes ble filtrert fra til å gi N-benzoyl-N'-[2-(2-tiazolylmetyltio)etyl]tiourea (20 g) smp. 90 - 91°C, som ble hydrolysert med 2,5 N kaliumhydroksyd i 20 min. ved 90°C til å gi N-[2-(2-tiazolylmetyltio)etyl]tiourea smp.
80 - 81°C (etanol).
b) En blanding av N-[2-(2-tiazolylmetyltio)etyl]tiourea (8,0 g), metyljodid (7,2 g) og metanol (100 ml) ble omrørt ved romtemperatur i 1,5 h. Eter (50 ml) ble tilsatt og faststoffet som ble separert ut ble omkrystallisert fra etanol/eter til å gi tittel-forbindelsen med smp. 150 - 151°C.
Claims (1)
- Analogifremgangsmåte ved fremstilling av farmakologisk aktive forbindelser med formelen (I):og salter derav,hvori er en gruppe med formel (II):hvori Het er en imidazolyl eller tiazolylgruppe, hvilke grupper eventuelt er substituert med en C-^_^-alkylgruppe, R^ er hydrogen, en C^_^-alkylgruppe eller en gruppe med formel (II), X er S eller NH, men ikke NH når R^ er hydrogen, og R^ er C-,_4-alkyl, karakterisert ved at en forbindelse med formelen (III):alkyleres med et alkyleringsmiddel som tilfører C-^_^-gruppen R^, og hvoretter når en forbindelse med formel (I) er ønsket hvori X er NH, omsette det erholdte produkt med et amin med formelen (IV):hvori R^ har den i forbindelse med formel (I) angitte betydning, hvoretter en forbindelse med formel (I) om ønskes omdannes til et salt.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB10869/74A GB1496787A (en) | 1974-03-12 | 1974-03-12 | Heteroalkylthioalkyl amidine derivatives |
Publications (3)
Publication Number | Publication Date |
---|---|
NO750809L NO750809L (no) | 1975-09-15 |
NO143381B true NO143381B (no) | 1980-10-20 |
NO143381C NO143381C (no) | 1981-01-28 |
Family
ID=9975816
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO750809A NO143381C (no) | 1974-03-12 | 1975-03-11 | Analogifremgangsmaate ved fremstilling av farmakologisk aktive guanidin- og isotioureaderivater |
NO794346A NO794346L (no) | 1974-03-12 | 1979-12-28 | Fremgangsmaate for fremstilling av farmakologisk aktive forbindelser |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO794346A NO794346L (no) | 1974-03-12 | 1979-12-28 | Fremgangsmaate for fremstilling av farmakologisk aktive forbindelser |
Country Status (19)
Country | Link |
---|---|
US (2) | US4036971A (no) |
JP (1) | JPS5946220B2 (no) |
BE (1) | BE825976A (no) |
CA (1) | CA1055505A (no) |
DE (1) | DE2510860A1 (no) |
DK (1) | DK74675A (no) |
ES (1) | ES435540A1 (no) |
FR (1) | FR2263765B1 (no) |
GB (1) | GB1496787A (no) |
HU (1) | HU171049B (no) |
IE (1) | IE40725B1 (no) |
IL (1) | IL46638A0 (no) |
LU (1) | LU72013A1 (no) |
NL (1) | NL7502935A (no) |
NO (2) | NO143381C (no) |
PH (1) | PH14072A (no) |
PL (1) | PL100317B1 (no) |
SE (1) | SE7502715L (no) |
ZA (1) | ZA75870B (no) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1496787A (en) * | 1974-03-12 | 1978-01-05 | Smith Kline French Lab | Heteroalkylthioalkyl amidine derivatives |
NZ186965A (en) | 1977-04-20 | 1980-02-21 | Ici Ltd | Guanidino derivatives and pharmaceutical compositions |
US4165378A (en) | 1977-04-20 | 1979-08-21 | Ici Americas Inc. | Guanidine derivatives of imidazoles and thiazoles |
IL57415A (en) * | 1978-05-30 | 1984-08-31 | Smith Kline French Lab | Nitropyrrole compounds,process for preparing them and pharmaceutical compositions containing them |
US4309435A (en) * | 1978-10-16 | 1982-01-05 | Imperial Chemical Industries Ltd. | Antisecretory guanidine derivatives and pharmaceutical compositions containing them |
US4262125A (en) * | 1979-07-23 | 1981-04-14 | American Home Products Corporation | (1H-Imidazol-5-ylmethyl)isothioureas |
US4382090A (en) * | 1980-10-02 | 1983-05-03 | Eli Lilly And Company | N-Thiazolylmethylthioalkyl-N'alkylamidines and related compounds |
IE53068B1 (en) * | 1981-06-15 | 1988-05-25 | Merck & Co Inc | Diamino isothiazole-1-oxides and -1,1-dioxides as gastic secretion inhibitors |
JP3003148B2 (ja) * | 1989-01-05 | 2000-01-24 | 藤沢薬品工業株式会社 | チアゾール化合物、その製造法およびそれを含有する医薬組成物 |
FR2883257B1 (fr) * | 2005-03-18 | 2007-06-01 | Thales Sa | Dispositif de compensation de jeu mecanique de commande de vol d'helicoptere |
WO2022034121A1 (en) | 2020-08-11 | 2022-02-17 | Université De Strasbourg | H2 blockers targeting liver macrophages for the prevention and treatment of liver disease and cancer |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3868457A (en) * | 1969-10-29 | 1975-02-25 | Smith Kline French Lab | Method of inhibiting histamine activity with guanidine compounds |
BE758146A (fr) * | 1969-10-29 | 1971-04-28 | Smith Kline French Lab | Derives de l'amidine |
US3734924A (en) * | 1970-10-14 | 1973-05-22 | Smith Kline French Lab | Carboxamidines |
GB1338169A (en) * | 1971-03-09 | 1973-11-21 | Smith Kline French Lab | Ureas thioureas and guanidines |
US3979398A (en) * | 1973-02-08 | 1976-09-07 | Smith Kline & French Laboratories Limited | Sulphoxides |
US4025527A (en) * | 1973-07-13 | 1977-05-24 | Smith Kline & French Laboratories Limited | Certain thiazoles and oxazoles |
GB1496787A (en) * | 1974-03-12 | 1978-01-05 | Smith Kline French Lab | Heteroalkylthioalkyl amidine derivatives |
US4118496A (en) * | 1974-03-12 | 1978-10-03 | Smith Kline & French Laboratories Limited | Heterocyclic-methylthioalkyl-amidines |
GB1497260A (en) * | 1974-06-28 | 1978-01-05 | Smith Kline French Lab | Guanidine derivatives |
GB1531231A (en) * | 1974-09-02 | 1978-11-08 | Smith Kline French Lab | Process for the production of cyanoguanidine derivatives |
US4120972A (en) * | 1975-02-03 | 1978-10-17 | Smith Kline & French Laboratories Limited | Imidazolylmethylthio-ethyl isothiourea compounds |
-
1974
- 1974-03-12 GB GB10869/74A patent/GB1496787A/en not_active Expired
-
1975
- 1975-02-11 ZA ZA00750870A patent/ZA75870B/xx unknown
- 1975-02-14 CA CA220,151A patent/CA1055505A/en not_active Expired
- 1975-02-14 IL IL46638A patent/IL46638A0/xx unknown
- 1975-02-19 US US05/551,220 patent/US4036971A/en not_active Expired - Lifetime
- 1975-02-19 IE IE340/75A patent/IE40725B1/xx unknown
- 1975-02-26 BE BE153733A patent/BE825976A/xx not_active IP Right Cessation
- 1975-02-26 DK DK74675*#A patent/DK74675A/da unknown
- 1975-03-04 FR FR7506687A patent/FR2263765B1/fr not_active Expired
- 1975-03-07 PH PH16881A patent/PH14072A/en unknown
- 1975-03-07 JP JP50028592A patent/JPS5946220B2/ja not_active Expired
- 1975-03-10 LU LU72013A patent/LU72013A1/xx unknown
- 1975-03-11 PL PL1975178679A patent/PL100317B1/pl unknown
- 1975-03-11 SE SE7502715A patent/SE7502715L/xx unknown
- 1975-03-11 NO NO750809A patent/NO143381C/no unknown
- 1975-03-12 NL NL7502935A patent/NL7502935A/xx not_active Application Discontinuation
- 1975-03-12 HU HU75SI00001458A patent/HU171049B/hu unknown
- 1975-03-12 DE DE19752510860 patent/DE2510860A1/de not_active Ceased
- 1975-03-12 ES ES435540A patent/ES435540A1/es not_active Expired
-
1979
- 1979-05-14 US US06/039,090 patent/US4282234A/en not_active Expired - Lifetime
- 1979-12-28 NO NO794346A patent/NO794346L/no unknown
Also Published As
Publication number | Publication date |
---|---|
ZA75870B (en) | 1976-01-28 |
CA1055505A (en) | 1979-05-29 |
NO143381C (no) | 1981-01-28 |
FR2263765B1 (no) | 1978-08-04 |
SE7502715L (no) | 1975-09-15 |
GB1496787A (en) | 1978-01-05 |
PH14072A (en) | 1981-01-26 |
DE2510860A1 (de) | 1975-09-18 |
IE40725L (en) | 1975-09-12 |
NL7502935A (nl) | 1975-09-16 |
NO794346L (no) | 1975-09-15 |
FR2263765A1 (no) | 1975-10-10 |
BE825976A (fr) | 1975-08-26 |
NO750809L (no) | 1975-09-15 |
AU7831175A (en) | 1976-08-19 |
JPS50129550A (no) | 1975-10-13 |
HU171049B (hu) | 1977-10-28 |
ES435540A1 (es) | 1976-12-16 |
US4282234A (en) | 1981-08-04 |
US4036971A (en) | 1977-07-19 |
LU72013A1 (no) | 1975-08-20 |
IL46638A0 (en) | 1975-04-25 |
JPS5946220B2 (ja) | 1984-11-10 |
IE40725B1 (en) | 1979-08-01 |
DK74675A (no) | 1975-09-13 |
PL100317B1 (pl) | 1978-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4347250A (en) | Pyridyl alkylthiourea and alkylamino-nitroethylene | |
US4034101A (en) | N-Oxy and N-amino guanidines | |
CA1045142A (en) | Cyanoguanidines | |
US4062863A (en) | Pharmacologically active cyclo butenediones | |
NO143381B (no) | Analogifremgangsmaate ved fremstilling av farmakologisk aktive guanidin- og isotioureaderivater | |
IE51946B1 (en) | Imidazolylphenyl amidines | |
US4375472A (en) | Amidinosulphonic acid derivatives | |
US3920822A (en) | Inhibition of histamine activity with cyanoguanidines | |
US4070472A (en) | Guanidino, thioureido, isothioureido and nitrovinylamino derivatives of pyridine | |
US4107319A (en) | Pharmacologically active compounds | |
GB1565647A (en) | Pharmacologically active compounds 4-substituted-imidazole-5-methanols | |
US4166856A (en) | Thiazole and isothiazole derivative as blockers of histamine H2 -receptors | |
EP0105458B1 (en) | Alpha-aryl-alpha-pyridylalkanoic acid derivatives, process for preparation thereof and pharmaceutical composition comprising the same | |
US4120973A (en) | Imidazolyl alkylaminocyclobutenediones | |
DD144056A5 (de) | Verfahren zur herstellung von als histamin h tief 2-rezeptor-antagonisten wirkenden nitroverbindungen | |
US4093729A (en) | N-Oxy and N-amino guanidines | |
US4133886A (en) | Guanidino, thioureido, isothioureido and nitrovinylamino derivatives of pyridine | |
US4160030A (en) | N-oxy and N-amino guanidines | |
US4191769A (en) | Isothiourea compounds and pharmacological use | |
US4192879A (en) | Imidazolyl alkylamino nitroethylene compounds | |
US4170652A (en) | Heterocyclic-methylthioalkyl-guanidines | |
US4126670A (en) | Method of stimulating histamine H2 -receptors | |
FI61308C (fi) | Analogifoerfarande foer framstaellning av terapeutiskt aktiva guanidinfoereningar | |
CA1068713A (en) | Process for preparing substituted guanidines | |
US4405621A (en) | Heterocyclic thioureas, isothioureas, guanidines and nitromethylene-amidines |